MY146420A - Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors - Google Patents

Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Info

Publication number
MY146420A
MY146420A MYPI20091013A MYPI20091013A MY146420A MY 146420 A MY146420 A MY 146420A MY PI20091013 A MYPI20091013 A MY PI20091013A MY PI20091013 A MYPI20091013 A MY PI20091013A MY 146420 A MY146420 A MY 146420A
Authority
MY
Malaysia
Prior art keywords
inhibitors
pyrido
pyrimidinone compounds
compounds
pyrimidinone
Prior art date
Application number
MYPI20091013A
Other languages
English (en)
Inventor
Cheng Hengmio
Plewe Michael Bruno
Tran Khanh Tuan
Bhumralkar Dilip
Dress Klaus Ruprecht
Hoffman Jacqui Elizabeth
Johnson Mary Catherine
Kania Robert Steven
Le Phuong Thi Quy
Nambu Mitchell David
Pairish Mason Alan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MY146420A publication Critical patent/MY146420A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
MYPI20091013A 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors MY146420A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84506506P 2006-09-15 2006-09-15
US94785207P 2007-07-03 2007-07-03
US95262807P 2007-07-30 2007-07-30

Publications (1)

Publication Number Publication Date
MY146420A true MY146420A (en) 2012-08-15

Family

ID=38859750

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20091013A MY146420A (en) 2006-09-15 2007-09-03 Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors

Country Status (41)

Country Link
US (3) US7696213B2 (https=)
EP (1) EP2074122B9 (https=)
JP (1) JP4718637B2 (https=)
KR (1) KR101099926B1 (https=)
CN (1) CN101573358B (https=)
AP (1) AP2710A (https=)
AR (1) AR062785A1 (https=)
AT (1) ATE514695T1 (https=)
AU (1) AU2007297212B8 (https=)
BR (1) BRPI0716749B8 (https=)
CA (1) CA2663401C (https=)
CL (1) CL2007002682A1 (https=)
CR (1) CR10662A (https=)
CU (1) CU23783B7 (https=)
CY (1) CY1111911T1 (https=)
DK (1) DK2074122T5 (https=)
DO (1) DOP2009000039A (https=)
EA (1) EA016388B1 (https=)
ES (1) ES2366489T3 (https=)
GE (1) GEP20115306B (https=)
GT (1) GT200700077A (https=)
HN (1) HN2007000267A (https=)
HR (1) HRP20110621T2 (https=)
IL (1) IL197243A (https=)
MA (1) MA30709B1 (https=)
ME (1) MEP8009A (https=)
MX (1) MX2009002927A (https=)
MY (1) MY146420A (https=)
NI (1) NI200900032A (https=)
NO (1) NO342357B1 (https=)
NZ (1) NZ575167A (https=)
PE (1) PE20080670A1 (https=)
PL (1) PL2074122T3 (https=)
PT (1) PT2074122E (https=)
RS (2) RS20090104A (https=)
SI (1) SI2074122T1 (https=)
TN (1) TN2009000085A1 (https=)
TW (1) TWI334353B (https=)
UY (1) UY30588A1 (https=)
WO (1) WO2008032162A1 (https=)
ZA (1) ZA200901477B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2074122T5 (da) * 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
JP2010523670A (ja) * 2007-04-10 2010-07-15 エクセリクシス, インク. Pi3kアルファのピリドピリミジノン阻害剤を使用した治療方法
CN101711249A (zh) * 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
KR20110028651A (ko) 2008-07-11 2011-03-21 노파르티스 아게 (a) 포스포이노시타이드 3-키나제 억제제 및 (b) ras/raf/mek 경로의 조절제의 조합물
TWI409265B (zh) 2008-08-20 2013-09-21 Merck Sharp & Dohme 經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP5619743B2 (ja) * 2008-08-20 2014-11-05 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. エテニル置換ピリジンおよびピリミジン誘導体およびウイルス感染の治療におけるそれらの使用
US8470834B2 (en) 2008-08-20 2013-06-25 Merck Sharp & Dohme Corp. AZO-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010039740A1 (en) * 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
CN103313989B (zh) 2010-12-16 2016-05-04 霍夫曼-拉罗奇有限公司 三环pi3k抑制剂化合物和使用方法
US8664230B2 (en) * 2011-03-17 2014-03-04 The Asan Foundation Pyridopyrimidine derivatives and use thereof
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
CN103764144B (zh) 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CN104829609B (zh) * 2014-02-11 2016-08-03 北大方正集团有限公司 取代的吡啶并嘧啶化合物及其制备方法和应用
KR20170032244A (ko) 2014-07-26 2017-03-22 선샤인 레이크 파르마 컴퍼니 리미티드 Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도
CN105330699B (zh) * 2014-08-13 2018-12-04 山东汇睿迪生物技术有限公司 一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
MX2017004580A (es) 2014-10-10 2017-06-27 Pfizer Combinaciones de auristatina sinergica.
MX376083B (es) 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
ES3002745T3 (en) 2016-07-06 2025-03-07 Univ Michigan Regents Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
US11241500B2 (en) * 2016-12-14 2022-02-08 Tarveda Therapeutics, Inc. HSP90-targeting conjugates and formulations thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
IL314362A (en) 2018-06-15 2024-09-01 Janssen Pharmaceutica Nv Rapamycin analogs and their uses
WO2020140053A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
WO2020140055A1 (en) * 2018-12-28 2020-07-02 Spv Therapeutics Inc. Cyclin-dependent kinase inhibitors
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
KR20220128345A (ko) 2019-12-05 2022-09-20 아나쿠리아 테라퓨틱스, 인코포레이티드 라파마이신 유사체 및 이의 용도
CN114901664B (zh) * 2020-01-10 2024-07-02 南京再明医药有限公司 吡啶酮化合物及应用
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
MX2023005747A (es) 2020-11-18 2023-07-28 Deciphera Pharmaceuticals Llc Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos.
EP4433061A4 (en) * 2021-11-18 2025-09-03 Onconova Therapeutics Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
KR20240113496A (ko) 2021-12-03 2024-07-22 데시페라 파마슈티칼스, 엘엘씨. Gcn2 및 perk 키나아제 억제제로서의 헤테로고리 화합물
EP4724070A2 (en) 2023-06-08 2026-04-15 Nimbus Wadjet, Inc. Wrn inhibitors
US20250206738A1 (en) * 2023-12-21 2025-06-26 Nimbus Wadjet, Inc. Wrn inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264437A (en) * 1992-03-20 1993-11-23 Syntex (U.S.A.) Inc. Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones
HUT76853A (en) 1994-11-14 1997-12-29 Warner Lambert Co 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6-取代的吡唑并[3,4-d]嘧啶-4-酮及其组合物和使用方法
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5925761A (en) 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6498163B1 (en) 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
GB9904932D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
KR20020070520A (ko) 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
PL358271A1 (pl) 2000-03-06 2004-08-09 Warner-Lambert Company 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
MXPA03007623A (es) 2001-02-26 2003-12-04 Tanabe Seiyaku Co Derivado de piridopirimidina o naftiridina.
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
ES2251677T3 (es) 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
KR20040103972A (ko) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
AU2003232071A1 (en) 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換6,6−ヘテロ二環式誘導体
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
WO2004089930A1 (en) 2003-04-02 2004-10-21 Imclone Systems Incorporated 4-fluoroquinolone derivatives and their use as kinase inhibitors
WO2005040337A2 (en) 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
ATE412650T1 (de) 2003-07-11 2008-11-15 Warner Lambert Co Isethionat salz eines selektiven cdk4 inhibitors
AU2004259755A1 (en) 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP1713806B1 (en) 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
BRPI0507852A (pt) 2004-02-18 2007-07-10 Warner Lambert Co 2-(piridin-3-ilamino)-pirido[2,3-d]pirimidin-7-onas
CA2561516A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
ATE373659T1 (de) * 2004-05-04 2007-10-15 Warner Lambert Co Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel
MXPA06014021A (es) 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
WO2006050501A2 (en) 2004-11-03 2006-05-11 University Of Kansas Novobiocin analogues as anticancer agents
AU2005316668B2 (en) 2004-12-13 2012-09-06 Millennium Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US20060142312A1 (en) 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
CN101395155A (zh) * 2005-10-07 2009-03-25 埃克塞里艾克西斯公司 PI3Kα的吡啶并嘧啶酮抑制剂
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP1872922A1 (en) * 2006-06-27 2008-01-02 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Method and apparatus for manufacturing a polymeric article
CN101528231A (zh) 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
DK2074122T5 (da) 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
CN101679308B (zh) * 2007-03-14 2014-05-07 埃克塞里艾克西斯公司 Hedgehog途径抑制剂
CN101711249A (zh) 2007-04-11 2010-05-19 埃克塞里艾克西斯公司 作为PI3K-α的抑制剂用于治疗癌症的吡啶并[2,3-D]嘧啶-7-酮化合物
WO2010039740A1 (en) 2008-09-30 2010-04-08 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR
AU2011239537A1 (en) * 2010-04-16 2012-11-15 Curis, Inc. Treatment of cancers having K-ras mutations

Also Published As

Publication number Publication date
EP2074122B9 (en) 2013-09-11
NZ575167A (en) 2010-10-29
GEP20115306B (https=) 2011-10-10
DK2074122T5 (da) 2014-03-17
EA016388B1 (ru) 2012-04-30
MA30709B1 (fr) 2009-09-01
AU2007297212B8 (en) 2011-04-28
EA200970207A1 (ru) 2009-08-28
MEP8009A (en) 2011-12-20
DK2074122T3 (da) 2011-08-15
IL197243A (en) 2013-07-31
AP2009004790A0 (en) 2009-04-30
ZA200901477B (en) 2010-07-28
NO20091141L (no) 2009-03-31
CU23783B7 (es) 2012-02-15
IL197243A0 (en) 2009-12-24
TW200820972A (en) 2008-05-16
CL2007002682A1 (es) 2008-04-04
ATE514695T1 (de) 2011-07-15
JP4718637B2 (ja) 2011-07-06
WO2008032162A1 (en) 2008-03-20
CY1111911T1 (el) 2015-11-04
AP2710A (en) 2013-07-30
TWI334353B (en) 2010-12-11
NI200900032A (es) 2010-05-14
BRPI0716749A2 (pt) 2014-02-18
BRPI0716749B1 (pt) 2020-10-06
HK1138589A1 (en) 2010-08-27
RS51927B (sr) 2012-02-29
JP2010503653A (ja) 2010-02-04
US20100137279A1 (en) 2010-06-03
ES2366489T3 (es) 2011-10-20
MX2009002927A (es) 2009-03-31
UY30588A1 (es) 2008-05-02
BRPI0716749B8 (pt) 2021-05-25
EP2074122A1 (en) 2009-07-01
AR062785A1 (es) 2008-12-03
US20120309775A1 (en) 2012-12-06
PE20080670A1 (es) 2008-06-14
NO342357B1 (no) 2018-05-14
DOP2009000039A (es) 2015-12-15
RS20090104A (sr) 2010-06-30
CN101573358A (zh) 2009-11-04
ES2366489T9 (es) 2013-12-27
AU2007297212B2 (en) 2011-04-14
CA2663401C (en) 2011-07-12
KR101099926B1 (ko) 2011-12-28
US20080090801A1 (en) 2008-04-17
PL2074122T3 (pl) 2011-10-31
EP2074122B1 (en) 2011-06-29
CA2663401A1 (en) 2008-03-20
HN2007000267A (es) 2011-02-25
CU20090040A7 (es) 2011-07-11
AU2007297212A1 (en) 2008-03-20
US8273755B2 (en) 2012-09-25
TN2009000085A1 (fr) 2010-08-19
US7696213B2 (en) 2010-04-13
CR10662A (es) 2009-04-17
HRP20110621T1 (hr) 2011-09-30
KR20090040389A (ko) 2009-04-23
WO2008032162A8 (en) 2009-03-26
US8633204B2 (en) 2014-01-21
HRP20110621T2 (hr) 2013-12-06
CN101573358B (zh) 2012-05-30
PT2074122E (pt) 2011-08-24
SI2074122T1 (sl) 2011-10-28
GT200700077A (es) 2009-08-03

Similar Documents

Publication Publication Date Title
MY146420A (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
EA201000113A1 (ru) Пиразольные соединения
WO2008039359A3 (en) Bicyclic pyrimidine kinase inhibitors
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
WO2007105058A8 (en) Pyrazole compounds
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2009008386A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pirimidina como inhibidores de proteinas de choque termico-90 para tratar cancer.
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2007115931A8 (de) Thiazolyl-dihydro-cyclopentapyrazole zur verwendung als pi3-kinase-inhibit0ren
EA200601391A1 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
WO2006047415A3 (en) FACTOR Xa COMPOUNDS
UY31161A1 (es) Usos de derivados de cinolina en el tratamiento de la esquizofrenia
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
TW200628153A (en) Novel compounds
UA93609C2 (en) 2-amino-5,6-dihydro-6h-pyrrolo[3, 4-d]pyrimidine derivatives as hsp-90 inhibitors for treating cancer
UA95113C2 (en) Pyrido (2,3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
MX2009013240A (es) Derivados de carboxamida heterociclicos, su uso farmaceutico y composiciones.
ATE522530T1 (de) 2-piperazin-1-yl-3h-imidazoä4,5-bü- pyridinderivate
UY32895A (es) Derivados acetilénicos de 5-fenilpirazolopiridina, su preparación y su aplicación terapéutica